

STEP THERAPY POLICY

POLICY: Ophthalmic – Glaucoma – Carbonic Anhydrase Inhibitors Step Therapy Policy

- Trusopt® (dorzolamide 2% ophthalmic solution – Merck, generic)

REVIEW DATE: 09/28/2022

OVERVIEW

Dorzolamide 2% ophthalmic solution is indicated in the treatment of **elevated intraocular pressure (IOP)** in patients with ocular hypertension or open-angle glaucoma.¹

POLICY STATEMENT

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

Automation: A patient with a of one Step 1 Product within the 130-day look-back period is excluded from Step Therapy.

Step 1: generic dorzolamide 2% ophthalmic solution

Step 2: Trusopt

CRITERIA

1. If the patient has tried one Step 1 drug, approve a Step 2 Product.
2. No other exceptions are recommended.

REFERENCES

1. Trusopt® ophthalmic solution [prescribing information]. Whitehouse Station, NJ: Merck; July 2021.